title: [Treatment-resistant bacterial infection in specific bacterial species and developmental movement of new antibiotics--Mycobacterium].
abstract: Mycobacterium tuberculosis and atypical mycobacteriosis are potent diseases which had not been curable before. Progress of chemotherapy has a marked effect but not enough results. We are now waiting for the appearance of a new medicine. Other rifamycim derivatives are developed as antimycobacterial agents, which have a mainframe of 3'-hydroxy-5'-alkylpiperazinyl-benzoxazinorifamycins (KRMs). KRMs exceeds RFP in bacteriostatic function, and also have already established in vivo in chemotherapeutic efficacy. Another study will also reveal a higher of bactericidal function. We expect possibility of much more powerful and short-term initial chemotherapy.
authors.affiliation: 1st Department of Medicine, Kurume University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Shiraishi
authors.forename: Y
authors.initials: Y
authors.lastname: Ichikawa
authors.forename: K
authors.initials: K
authors.lastname: Oizimi
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents